Dabigratan-related acute agranulocytosis
- PMID: 31013250
- PMCID: PMC6476740
- DOI: 10.2450/2019.0237-18
Dabigratan-related acute agranulocytosis
Conflict of interest statement
The Authors declare no conflicts of interest.
Comment on
-
Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre.Blood Transfus. 2018 Feb;16(2):209-214. doi: 10.2450/2017.0196-16. Epub 2017 Jan 30. Blood Transfus. 2018. PMID: 28287377 Free PMC article. Clinical Trial.
References
-
- Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93. - PubMed
-
- Hayashi H, Kitoh K, Mitsunami K, et al. Agranulocytosis immediately oral admistraion cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation. Intern Med. 2012;51:1987–90. - PubMed
-
- Fasullo S, Davì S, Cosenza G, et al. Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short literature review. J Thromb Thrombolysis. 2018;45:588–92. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical